JPS5867776A - Adhesive tape or sheet for remedy - Google Patents

Abstract

PURPOSE:The titled tape transferring a drug to the skin effectively with time, having stable remedying effect, obtained by applying a pressure-sensitive adhesive layer comprising the drug, and a polymer of an acrylic acid ester, etc. and a polymer of a vinyl alkyl ether in a specific ratio to a base material. CONSTITUTION:One side of a base material such as polyethylene, etc. is coated with a pressure-sensitive adhesive layer comprising a drug such as prednisolone, methyl salicylate, etc. and 50-95wt% polymer consisting of an acrylic acid ester (e.g., 2-ethylhexyl acrylate, etc.) and/or methacrylic acid ester (e.g., butyl methacrylate, etc.) as an ingredient and 50-5wt% polymer consisting of a vinyl alkyl ether (e.g., vinyl isobutyl ether, etc.) as an an ingredient, to give the desired tape. The amount of the drug is preferably 1mug-5mg based on 1cm<3> pressure-sensitive adhesive layer.

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention is suitable for the treatment of skin diseases, anti-inflammation, and analgesia.

BACKGROUND ART Conventionally, occlusive bandage therapy (OUT therapy), in which an external medicine such as an ointment is applied to the skin and a film is covered over the ointment to effectively absorb the medicine, has been widespread. However, with this tight forceps band therapy, not only is it difficult to attach the film to the affected area, but it is also bulky, easy to sting, and is difficult to apply when the affected area is large or the affected area is complex in shape. There was a 410 drawback that it was difficult to adhere. There are commercially available therapeutic tapes that eliminate these drawbacks by coating rolled, pressure-sensitive adhesives on an impermeable film. However, the pressure-sensitive adhesive used in such tapes must not come off during use and must be able to easily pierce the skin after use, and to balance this adhesive property, pressure-sensitive adhesives are usually used. When making pressure adhesives, it is necessary to use a suitable crosslinking agent.

However, the use of cross-linking agents has the disadvantages that the transfer of the drug to the skin deteriorates over time, and the drug contained in the pressure-sensitive adhesive layer cannot be used effectively, resulting in a gradual decline in therapeutic efficacy. .

For example, in conventional pressure-sensitive adhesives containing acrylic esters or (and) methacrylic esters as terlL units, a heptamer containing a functional group is copolymerized and an OS bridge agent such as an incyanate compound or a metal compound is used. As a result, the strength of cohesive force and adhesion ctst* is achieved.

However, such pressure-sensitive adhesives have the disadvantage that the adhesiveness of the drug to the skin deteriorates over time.

The purpose of the present invention is to eliminate the above-mentioned drawbacks, to ensure that the drug contained in the pressure-sensitive adhesive layer is effectively transferred to the skin, and that its transferability does not change over time and is always stable, thereby providing a therapeutic effect. As a therapeutic tape or sheet 1! Il is to serve.

The gist of the present invention is a therapeutic adhesive tape or sheet in which a pressure-sensitive adhesive layer containing a drug is provided on a piece of a base material O, in which the pressure-sensitive adhesive is 1, l) acrylic ester or (and ) A therapeutic adhesive tape or sheet containing 50-95% by weight of a polymer containing methacrylic acid ester as a constituent; (b) 50-5% by weight of a polymer containing vinyl alkyl ether as a constituent; Exists.

Next, the therapeutic adhesive tape or sheet of the present invention will be explained in more detail.

The base material used in the present invention may be a flexible material such as polyethylene, polypropylene, ethylene-vinyl acetate copolymer, soft polyvinyl chloride, or cellophane, or a surface of these materials may be treated with a 2a discharge or the like. -, etc. are preferably used. The thickness of the base material is Fiso ~ lO
A range of 0 microns is preferred.

A pressure sensitive adhesive layer is provided on the substrate. The pressure-sensitive adhesive layer is made of K) acrylic ester or Fi (and)
Polymer SO~9 containing methacrylic acid ester as a constituent component
Contains 50--S by weight of a polymer whose constituent components are vinyl urethane and (b) vinyl urethane.

Polymers containing acrylic esters or (and) methacrylic esters as constituent components include homopolymers of acrylic esters, copolymers of acrylic esters, homopolymers of methacrylic esters, and polymers of methacrylic esters. Copolymers of acrylic ester and methacrylic ester O copolymers, copolymers of acrylic ester and monomers copolymerizable with this, copolymers of methacrylic ester and other monomers copolymerizable with this, etc. means a copolymer etc. with a monomer of

Examples of the acrylic ester include ethyl acrylate, n-butyl acrylate, inbutyl acrylate, inamyl acrylate, and 2-ethylhexyl 1
Acrylate, a-octyl acrylate, lacryl acrylate, etc. are used, and methacrylic acid ester and Li2
, methyl methacrylate, butyl methacrylate, 2-
Ethylhexyl methacrylate, n-octyl methacrylate, tucryl methacrylate, etc. are used.

Polymers composed of vinyl alkyl ethers are homopolymers of vinyl alkyl ethers, copolymers of vinyl alkyl ethers, and copolymers of vinyl alkyl ethers with other monomers that can be copolymerized with the vinyl alkyl ethers. It means a copolymer, etc.

As the vinyl alkyl ether, for example, vinyl methyl ether, vinyl ethyl ether, vinyl ingtyl ether, etc. are used.

Examples of the other monomers used include acrylic acid, methacrylic acid, itaconic acid, acrylamide, vinyl acetate, acrylonitrile, and styrene.

The polymer containing the acrylic ester or (and) methacrylic ester as a constituent may migrate to the interface with the pressure-sensitive adhesive layer and the drug may not be used effectively, or the drug may not interact with the pressure-sensitive adhesive layer. 11111M paper and world di
The iK oozes out and transfers to the release paper, preventing it from being transferred effectively or having an adverse effect on the adhesion of the pressure-sensitive adhesive layer to the skin.

KF to ensure that the drug transfers efficiently to the skin surface.
i. It is required that the drug is dispersed in the pressure-sensitive adhesive layer, and therefore it is necessary that the drug and the pressure-sensitive adhesive have compatibility. Therefore, in the present invention, in order to improve the compatibility between a drug and a pressure-sensitive adhesive, a polymer tm acrylic ester or (and ) It is used in combination with a methacrylic acid ester polymer. However, since polymers containing vinyl 1-alkyl ether have good compatibility with drugs, they tend to interact with the functional groups of one drug, impairing the drug's ability to transfer to the skin. . Therefore, acrylic ester or Fi (and) methacrylic ester is used.
The composition of the polymer and vinyl alkyl ether as components
The ratio of polymer used is 50 to 95% by weight of the former.
The latter is said to be 50-5% by weight for 6◎Like this #
By adjusting the amount of both types of combination described in J, the transferability of the drug to the skin is improved, and the drug can be efficiently transferred from the pressure-sensitive adhesive layer to the surface of the skin.

If the polymer containing acrylic ester or (and -) methacrylic ester as a component is more than 9S weight%, and the polymer containing vinyl alkyl ether as component a is less than 5% by weight, In this case, it becomes difficult to efficiently transfer the drug to the surface of the skin between the base material and the pressure-sensitive adhesive layer. In addition, the polymer containing acrylic acid ester or (and) methacrylic acid ester as a constituent component is less than 50% by weight, and is composed of vinyl alkyl ether.
When the amount of polymer for L content is 50% by weight,
The influence of the interaction between the functional group of the drug and the polymer having vinyl alkyl ether as component a becomes strong, and the drug does not transfer sufficiently to the skin.

The drugs in the present invention include hydroflutidine, hydroflutidine acetate, prednisolone, daxamethasone,
Adrenocortical hormones such as betamethacin and fluocinoacetonide; methyl salicylate, monoglycol bricylate A/
A number 1 analgesic, an antihistamine, an anti-inflammatory agent, etc. are used as appropriate depending on the purpose.

The amount of the drug contained in the pressure-sensitive adhesive varies depending on the thickness of the pressure-sensitive adhesive layer, the type of drug, etc., but is preferably in the range of lpf to 5q per pressure-sensitive adhesive layer.

According to the present therapeutic adhesive tape (K), which is constructed as described above, it has good adhesion to the skin during use, is easy to remove from the skin after use, and is pressure sensitive. The drug contained in the W1 adhesive layer efficiently transfers to the skin, and its transferability does not change over time and is always stable, resulting in a therapeutic effect of 9%.

The present invention will be explained below using examples.

Example 1 80 parts by weight of 2-ethylhexyl acrylate, 20 parts by weight of butyl acrylate, 50 parts by weight of ethyl acetate, polymerization - Add 1 part by weight of peroxide pencil as an initiator and polymerize at 60°C for 48 hours under a nitrogen stream.
/ was dissolved in 65 weight 96 #l to prepare a nine-acetate ethyl solution.

Next, an ethyl acetate solution of the 2-ethylhexyl acrylate/butyl acrylate copolymer and polyvinyl isobutyl ether was added so as to contain 80 parts by weight of the 2-ethylhexyl acrylate off-ru acrylate copolymer and 20 parts by weight of polyvinyl isobutyl ether. Mix and add
slJ Call! After mixing 18 parts by weight of prednisolone II solution (prednisone a:methanol-1:4G in weight ratio), the mixture was coated on a polyethylene film to a thickness of 601 m. It was dried for 20 minutes. The content of prednisolone in this case was so pf, ;r:.

The therapeutic adhesive tape thus obtained was immersed in water for 5 hours, and the amount of nine pre-F nisolone extracted was determined.
A therapeutic adhesive tape was obtained in the same manner as in Example 1, except that in Example I, polyvinyl ingthyl ether was not present.

When the amount of prednisolone extracted from this therapeutic adhesive tape was measured in the same manner as in Example 1, it was found to be s5% by weight.

patent applicant Sekisui Chemical Co., Ltd. Representative: Mototoshi IK3

Claims (1)

[Claims] L 0 pieces of base material mK1 A therapeutic adhesive tape or sheet provided with a pressure-sensitive adhesive layer containing a drug, in which the pressure-sensitive adhesive comprises (a) acrylic ester or (and) ivy acrylic ester as a constituent component. A therapeutic adhesive tape or sheet containing 50 to 95% by weight of a polymer having the following properties and 50 to 5% by weight*1 of a polymer whose constituent components are (b) vinyl alkyl ether.